Little is known about the relationship between albuminuria in youth with type 2 diabetes (T2D) and cardiovascular risk. We aimed to determine if youth with T2D and albuminuria have evidence of increased cardiovascular risk and/or earlycardiovascular dysfunction compared to youth with T2D without albuminuria.
The Newfoundland and Labrador Diabetic Ketoacidosis Project (NLdkaP) is a multi-intervention, province-wide project aimed at lowering rates of diabetic ketoacidosis (DKA) within the pediatric and young adult populations.
Type 1 diabetes is characterized by the autoimmune destruction of insulin secreting β cells. Genetic variations upstream at the insulin (INS) locus contribute to ∼10% of type 1 diabetes heritable risk. Multiple studies showed an association between rs3842753 C/C genotype and type 1 diabetes susceptibility, but the molecular mechanisms remain unclear. To date, no large-scale studies have looked at the effect of genetic variation at rs3842753 on INS mRNA at the single cell level. We aligned all human islet single cell RNA sequencing datasets available to us in 2020 to the reference genome GRCh38.98 and genotyped rs3842753, integrating 2315 β cells and 1223 beta-like cells from 13 A/A protected donors, 23 A/C heterozygous donors, and 35 C/C at-risk donors, including adults without diabetes and with type 2 diabetes.
To investigate the association of erythropoietin gene polymorphisms with diabetic retinopathy in type 2 diabetes mellitus patients from north India.
Over the past decade, many Health Services Research (HSR) studies have been guided by the Triple Aim Framework, which was introduced by the Institute for Healthcare Improvement (www.ihi.org) in 2007, and includes 3 dimensions: “improving the individual experience of care; improving the health of populations; and reducing the per capita costs of care” (1). The Triple Aim has proven a useful framework for quality improvement and health systems research. This issue of the Canadian Journal of Diabetes features several articles that relate to one or more of the 3 aims: changing Alberta’s insulin pump therapy eligibility criteria to improve selection and safety of individuals living with diabetes (2); using sensor-based technology to improve glycemia in individuals with type 1 diabetes (3); switching primary care providers from fee-for-service to capitation-based remuneration to improve diabetes care (4); and combining SGLT2 inhibitors with GLP-1 receptor agonists to improve cardiorenal outcomes (5), among others.
Even though quality of care in the prevention and management of diabetic foot ulceration (DFU) is improved with the use of comprehensive evidence-based clinical practice guidelines, disparities between national and international guidelines have been demonstrated in one previous study conducted in Western Pacific regions. Although there are challenges of systematic implementation of evidence-base cares in some clinical settings, their applications have demonstrated positive outcomes on DFU associated burdens in many countries.
Study objectives were to document the screening rate for cystic fibrosis-related diabetes (CFRD) in children followed at a cystic fibrosis (CF) clinic in Canada and evaluate the accuracy of various glycated hemoglobin (A1C) cut-offs to screen for CFRD and impaired glucose tolerance (IGT) in a pediatric CF population.
The events and people surrounding the discovery of insulin as an effective therapy for diabetes in 1921 represent a compelling story that is directly relevant to the lives, and indeed the existence of tens of millions of people worldwide. This story begins in the 19th century with the recognition that diabetes is a disease of hyperglycemia that arises because of the absence of a pancreatic hormone, that rapidly leads to death in people classified as having “thin diabetes”, and that is linked to serious end-organ damage and other health consequences in people identified as having “fat diabetes”.
To identify pediatric patients presenting in Diabetic Ketoacidosis (DKA) who received initial treatment inconsistent with current guidelines, and track associated complications.
To compare healthcare visits pre and post transition from pediatric to adult care between youth with type 2 and type 1 diabetes.
The objective was to answer the main research question: In patients with diabetes, does virtual care vs. face to face care provide different clinical, patient and practitioner experience or quality outcomes? Articles (2012-2020) describing interventions using virtual care with capability for 2-way, individualized interactions compared with usual care were included. Studies involving any patients with diabetes and outcomes of A1C, quality of care and/or patient or HCP experience were included. Systematic reviews, randomized controlled, quasi-experimental, implementation trials, observational studies and qualitative analyses were reviewed.
Despite advances in technology and type 1 diabetes (T1D) care, children from low-income families continue to have suboptimal outcomes and increased health-care utilization. In this study, we describe social determinants of health (SDOH) in high-risk children with T1D, as well as their SDOH-related priority goals, and assess the correlation between SDOH, glycemic control and health-care utilization.
Understanding of patient experiences and adaptations to hybrid closed-loop (HCL) pumps beyond the confines of short-term clinical trials is needed to inform best practices surrounding this emerging technology. We investigated long-term, real-world patient experiences with HCL technology.
Canadian Journal of Diabetes RSS feed.
Subscribe to Canadian Journal of Diabetes feed